Patents by Inventor Raymond J. Andersen

Raymond J. Andersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bisphenol derivatives and their use as androgen receptor activity modulators
    Patent number: 11919874
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
    Type: Grant
    Filed: August 17, 2021
    Date of Patent: March 5, 2024
    Assignees: The University of British Columbia, Provincial Health Services Authority
    Inventors: Raymond J. Andersen, Marianne Dorothy Sadar, Kunzhong Jian, Nasrin R. Mawji, Jun Wang, Carmen Adriana Banuelos, Yu-Chi Yang
  • BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS
    Publication number: 20210387957
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
    Type: Application
    Filed: August 17, 2021
    Publication date: December 16, 2021
    Inventors: Raymond J. Andersen, Marianne Dorothy Sadar, Kunzhong Jian, Nasrin R. Mawji, Jun Wang, Carmen Adriana Banuelos, Yu-Chi Yang
  • Bisphenol derivatives and their use as androgen receptor activity modulators
    Patent number: 11142508
    Abstract: Compounds having a structure of Formula I or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: October 12, 2021
    Assignees: The University of British Columbia, Provincial Health Services Authority
    Inventors: Raymond J. Andersen, Marianne Dorothy Sadar, Kunzhong Jian, Nasrin R. Mawji, Jun Wang, Carmen Adriana Banuelos, Yu-Chi Yang
  • BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS
    Publication number: 20200317628
    Abstract: Compounds having a structure of Formula I or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
    Type: Application
    Filed: April 14, 2020
    Publication date: October 8, 2020
    Inventors: Raymond J. Andersen, Marianne Dorothy Sadar, Kunzhong Jian, Nasrin R. Mawji, Jun Wang, Carmen Adriana Banuelos, Yu-Chi Yang
  • Mammalian glucosidase inhibitors, methods for their use and pharmaceutical compositions thereof
    Patent number: 10583167
    Abstract: Provided are methods, uses and pharmaceutical compositions for inhibition of mammalian alpha-amylase in a subject, with a Helianthamide peptide or a derivative thereof in a biologically effective amount. The subject in need of alpha-amylase inhibition, may have or be at risk of developing one or more of the following: Middleton syndrome; a motility disorder of the gastrointestinal tract; postprandial reactive hypoglycemia; postprandial syndrome; irritable bowel syndrome; diabetes mellitus type 1; diabetes mellitus type 2; pre-diabetes; obesity, dumping syndrome; infant dumping syndrome; polycystic ovary syndrome; steatohepatitis; and viral infection.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: March 10, 2020
    Assignee: THE UNIVERSITY OF BRITISH COLUMBIA
    Inventors: Stephen G. Withers, Andrew Tarling, Raymond J. Andersen, Gary D. Brayer, Robert Keyzers, Christina Rose Tysoe, Leslie Karen Williams
  • Androgen receptor modulators and methods for their use
    Patent number: 10071962
    Abstract: Compounds having a structure of Structure I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R4, R6, Y1 and Y2 are as defined herein, and wherein at least one of R3 or R4 is a straight-chain C1-C6 haloalkyl, are provided. Uses of such compounds for treatment of various indications, including prostate cancer, as well as methods of treatment involving such compounds are also provided.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: September 11, 2018
    Assignees: British Columbia Cancer Agency Branch, The University of British Columbia
    Inventors: Luping Yan, Raymond J. Andersen, Marianne Dorothy Sadar, Nasrin R. Mawji, Carmen Adriana Banuelos
  • MAMMALIAN GLUCOSIDASE INHIBITORS, METHODS FOR THEIR USE AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20180193413
    Abstract: Provided are methods, uses and pharmaceutical compositions for inhibition of mammalian alpha-amylase in a subject, with a Helianthamide peptide or a derivative thereof in a biologically effective amount. The subject in need of alpha-amylase inhibition, may have or be at risk of developing one or more of the following: Middleton syndrome; a motility disorder of the gastrointestinal tract; postprandial reactive hypoglycemia; postprandial syndrome; irritable bowel syndrome; diabetes mellitus type 1; diabetes mellitus type 2; pre-diabetes; obesity, dumping syndrome; infant dumping syndrome; polycystic ovary syndrome; steatohepatitis; and viral infection.
    Type: Application
    Filed: June 29, 2016
    Publication date: July 12, 2018
    Inventors: Stephen G. WITHERS, Andrew TARLING, Raymond J. ANDERSEN, Gary D. BRAYER, Robert KEYZERS, Christina Rose TYSOE, Leslie Karen WILLIAMS
  • Diglycidic ether derivative therapeutics and methods for their use
    Patent number: 9862667
    Abstract: This invention provides compound having a structure of Formula I or Formula II. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
    Type: Grant
    Filed: July 2, 2009
    Date of Patent: January 9, 2018
    Assignees: THE UNIVERSITY OF BRITISH COLUMBIA, BRITISH COLUMBIA CANCER AGENCY BRANCH
    Inventors: Marianne D. Sadar, Nasrin R. Mawji, Jun Wang, Raymond J. Andersen, David E. Williams, Mike Leblanc
  • ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE
    Publication number: 20170283377
    Abstract: Compounds having a structure of Structure I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R4, R6, Y1 and Y2 are as defined herein, and wherein at least one of R3 or R4 is a straight-chain C1-C6 haloalkyl, are provided. Uses of such compounds for treatment of various indications, including prostate cancer, as well as methods of treatment involving such compounds are also provided.
    Type: Application
    Filed: June 19, 2017
    Publication date: October 5, 2017
    Inventors: Luping YAN, Raymond J. ANDERSEN, Marianne Dorothy SADAR, Nasrin R. MAWJI, Carmen Adriana Banuelos
  • SMALL MOLECULE INHIBITORS OF N-TERMINUS ACTIVATION OF THE ANDROGEN RECEPTOR
    Publication number: 20170239216
    Abstract: Compounds having a structure of Formula (A) are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are provided. Uses of compounds having a structure of Formula (F) for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
    Type: Application
    Filed: September 27, 2016
    Publication date: August 24, 2017
    Inventors: Marianne D. SADAR, Nasrin R. MAWJI, Jun WANG, Raymond J. ANDERSEN, David E. WILLIAMS, Mike LEBLANC, Lu-Ping YAN
  • Androgen receptor modulators and methods for their use
    Patent number: 9682933
    Abstract: Compounds having a structure of Structure I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R4, R6, Y1 and Y2 are as defined herein, and wherein at least one of R3 or R4 is a straight-chain C1-C6 haloalkyl, are provided. Uses of such compounds for treatment of various indications, including prostate cancer, as well as methods of treatment involving such compounds are also provided.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: June 20, 2017
    Assignees: British Columbia Cancer Agency Branch, The University of British Columbia
    Inventors: Luping Yan, Raymond J. Andersen, Marianne Dorothy Sadar, Nasrin R. Mawji, Carmen Adriana Banuelos
  • Small molecule inhibitors of N-terminus activation of the androgen receptor
    Patent number: 9487479
    Abstract: Compounds having a structure of Formula (A) are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are provided. Uses of compounds having a structure of Formula (F) for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
    Type: Grant
    Filed: August 24, 2009
    Date of Patent: November 8, 2016
    Assignees: The University of British Columbia, British Columbia Cancer Agency Branch
    Inventors: Marianne D. Sadar, Nasrin R. Mawji, Jun Wang, Raymond J. Andersen, David E. Williams, Mike Leblanc, Lu-Ping Yan
  • Bisphenol derivatives and their use as androgen receptor activity modulators
    Patent number: 9388112
    Abstract: This invention provides bisphenol derivatives having a structure of formula 1. Said compounds are modulators of the androgen receptor activity and are useful in the treatment of various diseases, including prostate cancer, breast cancer, ovarian cancer, endometrial cancer, acne, ovarian cysts, polycystic ovarian disease, age-related macular degeneration, precocious puberty, hirsutism and hair loss.
    Type: Grant
    Filed: January 6, 2011
    Date of Patent: July 12, 2016
    Assignees: The University of British Columbia, Brittish Columbia Cancer Agency Branch
    Inventors: Marianne D. Sadar, Nasrin R. Mawji, Carmen Adriana Banuelos, Raymond J. Andersen, Javier Garcia Fernandez
  • ESTER DERIVATIVES OF ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE
    Publication number: 20160068466
    Abstract: Compounds having a structure of Structure I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R2, R3, R4, R5, J1, J2, X, Z, n1 and n2 are as defined herein, and wherein at least one of R1, R2 or R3 is an alkyl, alkenyl, aryl or aralkyl ester, are provided. Uses of such compounds for treatment of various indications, including prostate cancer, as well as methods of treatment involving such compounds are also provided.
    Type: Application
    Filed: September 3, 2015
    Publication date: March 10, 2016
    Applicants: The University of British Columbia, British Columbia Cancer Agency Branch
    Inventors: Raymond J. Andersen, Marianne D. Sadar, Javier Garcia Fernandez, Nasrin R. Mawji, Jun Wang, Carmen Adriana Banuelos
  • ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE
    Publication number: 20150344424
    Abstract: Compounds having a structure of Structure I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R4, R6, Y1 and Y2 are as defined herein, and wherein at least one of R3 or R4 is a straight-chain C1-C6 haloalkyl, are provided. Uses of such compounds for treatment of various indications, including prostate cancer, as well as methods of treatment involving such compounds are also provided.
    Type: Application
    Filed: May 29, 2015
    Publication date: December 3, 2015
    Inventors: Luping Yan, Raymond J. Andersen, Marianne Dorothy Sadar, Nasrin R. Mawji, Carmen Adriana Banuelos
  • Ester derivatives of androgen receptor modulators and methods for their use
    Patent number: 9173939
    Abstract: Compounds having a structure of Structure I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R2, R3, R4, R5, J1, J2, X, Z, n1 and n2 are as defined herein, and wherein at least one of R1, R2 or R3 is an alkyl, alkenyl, aryl or aralkyl ester, are provided. Uses of such compounds for treatment of various indications, including prostate cancer, as well as methods of treatment involving such compounds are also provided.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: November 3, 2015
    Assignees: The University of British Columbia, British Columbia Cancer Agency Branch
    Inventors: Raymond J. Andersen, Marianne D. Sadar, Javier Garcia Fernandez, Nasrin R. Mawji, Jun Wang, Carmen Adriana Banuelos
  • ESTER DERIVATIVES OF ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE
    Publication number: 20140335080
    Abstract: Compounds having a structure of Structure I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R2, R3, R4, R5, J1, J2, X, Z, n1 and n2 are as defined herein, and wherein at least one of R1, R2 or R3 is an alkyl, alkenyl, aryl or aralkyl ester, are provided. Uses of such compounds for treatment of various indications, including prostate cancer, as well as methods of treatment involving such compounds are also provided.
    Type: Application
    Filed: May 9, 2014
    Publication date: November 13, 2014
    Applicants: The University of British Columbia, British Columbia Cancer Agency Branch
    Inventors: Raymond J. Andersen, Marianne D. Sadar, Javier Garcia Fernandez, Nasrin R. Mawji, Jun Wang, Carmen Adriana Banuelos
  • Diglycidic ether derivative therapeutics and methods for their use
    Patent number: 8686050
    Abstract: This invention provides compound having a structure of Formula I or Formula II Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
    Type: Grant
    Filed: April 19, 2013
    Date of Patent: April 1, 2014
    Assignees: The University of British Columbia, British Columbia Cancer Agency Branch
    Inventors: Marianne D. Sadar, Nasrin R. Mawji, Jun Wang, Raymond J. Andersen, David E. Williams, Mike Leblanc
  • DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE
    Publication number: 20130245129
    Abstract: This invention provides compound having a structure of Formula I or Formula II Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
    Type: Application
    Filed: April 19, 2013
    Publication date: September 19, 2013
    Applicants: The University of British Columbia, British Columbia Cancer Agency Branch
    Inventors: Marianne D. Sadar, Nasrin R. Mawji, Jun Wang, Raymond J. Andersen, David E. Williams, Mike Leblanc
  • Sterol glucoside toxins
    Patent number: 8497123
    Abstract: The invention relates to the identification of sterol glucoside toxins, and provides methods for detecting and detoxifying the compounds, as well as therapeutic methods for treating subjects exposed to such toxins. In alternative embodiments, the toxins may for example include beta-sitostrol-beta-D-glucoside (5-cholesten-24b-ethyl-3b-ol-D-glucoside) or cholesterol glucoside (5-cholesten-3b-ol-3b-D-glucoside).
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: July 30, 2013
    Assignee: Neurodyn, Inc.
    Inventors: Christohper A. Shaw, Raymond J. Andersen, David E. Williams, Jaswinder Bains